- Home
- HAFN vs IOVA Comparison
HAFN vs IOVA Comparison
Compare HAFN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- IOVA
- Stock Information
- Founded
- HAFN 2012
- IOVA 2007
- Country
- HAFN Singapore
- IOVA United States
- Employees
- HAFN N/A
- IOVA N/A
- Industry
- HAFN
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HAFN
- IOVA Health Care
- Exchange
- HAFN Nasdaq
- IOVA Nasdaq
- Market Cap
- HAFN 2.7B
- IOVA 771.4M
- IPO Year
- HAFN N/A
- IOVA N/A
- Fundamental
- Price
- HAFN $5.10
- IOVA $1.75
- Analyst Decision
- HAFN Strong Buy
- IOVA Buy
- Analyst Count
- HAFN 1
- IOVA 10
- Target Price
- HAFN $6.50
- IOVA $12.22
- AVG Volume (30 Days)
- HAFN 1.5M
- IOVA 11.7M
- Earning Date
- HAFN 08-27-2025
- IOVA 08-07-2025
- Dividend Yield
- HAFN 17.97%
- IOVA N/A
- EPS Growth
- HAFN N/A
- IOVA N/A
- EPS
- HAFN 1.20
- IOVA N/A
- Revenue
- HAFN $2,631,664,000.00
- IOVA $212,679,000.00
- Revenue This Year
- HAFN N/A
- IOVA $86.62
- Revenue Next Year
- HAFN $1.88
- IOVA $69.95
- P/E Ratio
- HAFN $4.23
- IOVA N/A
- Revenue Growth
- HAFN N/A
- IOVA 11070.12
- 52 Week Low
- HAFN $3.61
- IOVA $1.64
- 52 Week High
- HAFN $8.37
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- IOVA 38.67
- Support Level
- HAFN N/A
- IOVA $1.67
- Resistance Level
- HAFN N/A
- IOVA $1.82
- Average True Range (ATR)
- HAFN 0.00
- IOVA 0.12
- MACD
- HAFN 0.00
- IOVA -0.01
- Stochastic Oscillator
- HAFN 0.00
- IOVA 13.64
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.